comparemela.com

Latest Breaking News On - Xbiotech company profile - Page 5 : comparemela.com

StockNews.com Initiates Coverage on Moleculin Biotech (NASDAQ:MBRX)

StockNews.com began coverage on shares of Moleculin Biotech (NASDAQ:MBRX – Get Rating) in a research report issued on Thursday. The brokerage set a “sell” rating on the stock. MBRX stock opened at $1.39 on Thursday. Moleculin Biotech has a twelve month low of $1.02 and a twelve month high of $3.99. The business has a […]

Morgan-stanley
Moleculin-biotech-inc
Goldman-sachs-group-inc
Sigma-planning-corp
Virtu-financial
Moleculin-biotech-company-profile-get-rating
Renaissance-technologies
Moleculin-biotech
Get-rating
Planning-corp
Goldman-sachs-group

Kane Biotech (KNE) Set to Announce Earnings on Thursday

Kane Biotech (CVE:KNE – Get Rating) is scheduled to release its earnings data after the market closes on Thursday, May 26th. Kane Biotech (CVE:KNE – Get Rating) last announced its quarterly earnings data on Thursday, March 24th. The company reported C($0.01) earnings per share (EPS) for the quarter. The firm had revenue of C$0.41 million […]

Canada
Kane-biotech-inc
Kane-biotech-company-profile-get-rating
Kane-biotech
Get-rating
Xbiotech-company-profile
Biotech-inc
Cve-kne
Skne
Medical
Earnings

Oncolytics Biotech (NASDAQ:ONCY) Downgraded to Hold at Zacks Investment Research

Read the latest stock market news on MarketBeat. Get real-time analyst ratings, dividend information, earnings results, financials, headlines, insider trades and options data for any stock.

Leede-jones-gab
Morgan-stanley
Oncolytics-biotech-inc
Long-focus-capital-management
Zacks-investment-research
Renaissance-technologies
Advisor-resource-council
Oncolytics-biotech
Canaccord-genuity-group
Oncolytics-biotech-company-profile-get-rating
Citadel-advisors
Get-rating

Krystal Biotech (NASDAQ:KRYS) Upgraded to "Buy" by Zacks Investment Research

Krystal Biotech (NASDAQ:KRYS – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Thursday, Zacks.com reports. The brokerage currently has a $71.00 price objective on the stock. Zacks Investment Research‘s price target indicates a potential upside of 6.67% […]

Arizona
United-states
America
Dekabank-deutsche-girozentrale
Krystal-biotech-inc
Zacks-investment-research
Commonwealth-equity-services
C-worldwide-group-holding
Worldwide-group-holding
Krystal-biotech-company-profile-get-rating
Goldman-sachs-group
Merriman-wealth-management

Krystal Biotech (NASDAQ:KRYS) & Cardiff Oncology (NASDAQ:CRDF) Financial Survey

Krystal Biotech (NASDAQ:KRYS – Get Rating) and Cardiff Oncology (NASDAQ:CRDF – Get Rating) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations and institutional ownership. Volatility & Risk Krystal Biotech has a beta of […]

California
United-states
San-diego
Pennsylvania
Krystal-biotech-inc
Cardiff-oncology-inc
Cardiff-oncology-company-profile-get-rating
Krystal-biotech-company-profile-get-rating
Trovagene-inc
Krystal-biotech
Get-rating

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.